ALMR (Alamar Biosciences) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALMR Alamar Biosciences Inc ALMR
12 GF Score
Price $34.85
! 1 Warning Sign
View Full Analysis

What is Alamar Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Alamar Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Alamar Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $9.95 Mil. Alamar Biosciences's annualized EBITDA for the quarter that ended in Jun. 2026 was $-47.74 Mil. Alamar Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.21.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Alamar Biosciences's Debt-to-EBITDA or its related term are showing as below:

ALMR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.67   Med: -1.23   Max: -0.79
Current: -1.64

During the past 2 years, the highest Debt-to-EBITDA Ratio of Alamar Biosciences was -0.79. The lowest was -1.67. And the median was -1.23.

ALMR's Debt-to-EBITDA is ranked worse than
100% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs ALMR: -1.64

Alamar Biosciences  (NAS:ALMR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Alamar Biosciences Debt-to-EBITDA Related Terms

Alamar Biosciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Alamar Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alamar Biosciences Debt-to-EBITDA Chart

Alamar Biosciences Annual Data
Trend Dec24 Dec25
Debt-to-EBITDA
-6.42 -11.11

Alamar Biosciences Quarterly Data
Mar25 Jun25 Mar26 Jun26
Debt-to-EBITDA N/A N/A N/A N/A

ALMR vs ESTA, NVCR, BFLY: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, Alamar Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alamar Biosciences Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alamar Biosciences's Debt-to-EBITDA falls into.


ALMR
12GF Score
Alamar Biosciences Inc ALMR
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alamar Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Alamar Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 244.806) / -24.889
=-9.84

Alamar Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 9.947) / -47.736
=-0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Alamar Biosciences Business Description

Address 47071 Bayside Parkway, Fremont, CA, USA, 94538
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score

Get the complete analysis for ALMR

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.85
Price